Fase III que utiliza Nab-Paclitaxel + Carboplatino y Pembrolizumab en NSCLC escamoso. El hazard ratio favorece a Nab paclitaxel en el análisis de subgrupos.
Randomized comparison of adjuvant aromatase inhibitor exemestane (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone receptor positive (HR+) early breast cancer (BC):
Chair and Presenter, Jonathan D. Spicer, MD, PhD, FRCSC, Sara Najmeh, MD, and Paula A. Ugalde Figueroa, MD, prepared useful Practice Aids pertaining to NSCLC for this CME/MOC activity titled “Neoadjuvant, Adjuvant, or Both: How to Solve the Puzzle of Perioperative Immunotherapy, Individualize Treatment Plans, and Improve Cure Rates in Resectable NSCLC.” For the full presentation, downloadable Practice Aids, and complete CME/MOC information, and to apply for credit, please visit us at https://bit.ly/3K8tKH9. CME/MOC credit will be available until June 5, 2024.
Randomized comparison of adjuvant aromatase inhibitor exemestane (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone receptor positive (HR+) early breast cancer (BC):
Chair and Presenter, Jonathan D. Spicer, MD, PhD, FRCSC, Sara Najmeh, MD, and Paula A. Ugalde Figueroa, MD, prepared useful Practice Aids pertaining to NSCLC for this CME/MOC activity titled “Neoadjuvant, Adjuvant, or Both: How to Solve the Puzzle of Perioperative Immunotherapy, Individualize Treatment Plans, and Improve Cure Rates in Resectable NSCLC.” For the full presentation, downloadable Practice Aids, and complete CME/MOC information, and to apply for credit, please visit us at https://bit.ly/3K8tKH9. CME/MOC credit will be available until June 5, 2024.
monarchE trial studied the benefit of adding abimaciclib to endocrine therapy (the standard of care for HR+/Her- early breast cancer) compared to endocrine therapy alone.
This deals with the current paradigm of treatment of osteosarcoma. It is an honest effort to clear the prevailing confusion in the treatment of osteosarcoma. I would be happy to get anyone
Report Back from San Antonio Breast Cancer Symposium (SABCS 2022)bkling
Curious about the latest developments in Early-Stage Breast Cancer and Metastatic Breast Cancer Research? Join us as Dr. Anne Blaes, the Division Director of Hematology/Oncology/Transplantation and Professor in Hematology/Oncology at the University of Minnesota, breaks down the most recent developments released at the annual San Antonio Breast Cancer Symposium regarding early-stage and metastatic breast cancer research.
monarchE trial studied the benefit of adding abimaciclib to endocrine therapy (the standard of care for HR+/Her- early breast cancer) compared to endocrine therapy alone.
This deals with the current paradigm of treatment of osteosarcoma. It is an honest effort to clear the prevailing confusion in the treatment of osteosarcoma. I would be happy to get anyone
Report Back from San Antonio Breast Cancer Symposium (SABCS 2022)bkling
Curious about the latest developments in Early-Stage Breast Cancer and Metastatic Breast Cancer Research? Join us as Dr. Anne Blaes, the Division Director of Hematology/Oncology/Transplantation and Professor in Hematology/Oncology at the University of Minnesota, breaks down the most recent developments released at the annual San Antonio Breast Cancer Symposium regarding early-stage and metastatic breast cancer research.
Prix Galien International 2024 Forum ProgramLevi Shapiro
June 20, 2024, Prix Galien International and Jerusalem Ethics Forum in ROME. Detailed agenda including panels:
- ADVANCES IN CARDIOLOGY: A NEW PARADIGM IS COMING
- WOMEN’S HEALTH: FERTILITY PRESERVATION
- WHAT’S NEW IN THE TREATMENT OF INFECTIOUS,
ONCOLOGICAL AND INFLAMMATORY SKIN DISEASES?
- ARTIFICIAL INTELLIGENCE AND ETHICS
- GENE THERAPY
- BEYOND BORDERS: GLOBAL INITIATIVES FOR DEMOCRATIZING LIFE SCIENCE TECHNOLOGIES AND PROMOTING ACCESS TO HEALTHCARE
- ETHICAL CHALLENGES IN LIFE SCIENCES
- Prix Galien International Awards Ceremony
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
Acute scrotum is a general term referring to an emergency condition affecting the contents or the wall of the scrotum.
There are a number of conditions that present acutely, predominantly with pain and/or swelling
A careful and detailed history and examination, and in some cases, investigations allow differentiation between these diagnoses. A prompt diagnosis is essential as the patient may require urgent surgical intervention
Testicular torsion refers to twisting of the spermatic cord, causing ischaemia of the testicle.
Testicular torsion results from inadequate fixation of the testis to the tunica vaginalis producing ischemia from reduced arterial inflow and venous outflow obstruction.
The prevalence of testicular torsion in adult patients hospitalized with acute scrotal pain is approximately 25 to 50 percent
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Title: Sense of Taste
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the structure and function of taste buds.
Describe the relationship between the taste threshold and taste index of common substances.
Explain the chemical basis and signal transduction of taste perception for each type of primary taste sensation.
Recognize different abnormalities of taste perception and their causes.
Key Topics:
Significance of Taste Sensation:
Differentiation between pleasant and harmful food
Influence on behavior
Selection of food based on metabolic needs
Receptors of Taste:
Taste buds on the tongue
Influence of sense of smell, texture of food, and pain stimulation (e.g., by pepper)
Primary and Secondary Taste Sensations:
Primary taste sensations: Sweet, Sour, Salty, Bitter, Umami
Chemical basis and signal transduction mechanisms for each taste
Taste Threshold and Index:
Taste threshold values for Sweet (sucrose), Salty (NaCl), Sour (HCl), and Bitter (Quinine)
Taste index relationship: Inversely proportional to taste threshold
Taste Blindness:
Inability to taste certain substances, particularly thiourea compounds
Example: Phenylthiocarbamide
Structure and Function of Taste Buds:
Composition: Epithelial cells, Sustentacular/Supporting cells, Taste cells, Basal cells
Features: Taste pores, Taste hairs/microvilli, and Taste nerve fibers
Location of Taste Buds:
Found in papillae of the tongue (Fungiform, Circumvallate, Foliate)
Also present on the palate, tonsillar pillars, epiglottis, and proximal esophagus
Mechanism of Taste Stimulation:
Interaction of taste substances with receptors on microvilli
Signal transduction pathways for Umami, Sweet, Bitter, Sour, and Salty tastes
Taste Sensitivity and Adaptation:
Decrease in sensitivity with age
Rapid adaptation of taste sensation
Role of Saliva in Taste:
Dissolution of tastants to reach receptors
Washing away the stimulus
Taste Preferences and Aversions:
Mechanisms behind taste preference and aversion
Influence of receptors and neural pathways
Impact of Sensory Nerve Damage:
Degeneration of taste buds if the sensory nerve fiber is cut
Abnormalities of Taste Detection:
Conditions: Ageusia, Hypogeusia, Dysgeusia (parageusia)
Causes: Nerve damage, neurological disorders, infections, poor oral hygiene, adverse drug effects, deficiencies, aging, tobacco use, altered neurotransmitter levels
Neurotransmitters and Taste Threshold:
Effects of serotonin (5-HT) and norepinephrine (NE) on taste sensitivity
Supertasters:
25% of the population with heightened sensitivity to taste, especially bitterness
Increased number of fungiform papillae
New Drug Discovery and Development .....NEHA GUPTA
The "New Drug Discovery and Development" process involves the identification, design, testing, and manufacturing of novel pharmaceutical compounds with the aim of introducing new and improved treatments for various medical conditions. This comprehensive endeavor encompasses various stages, including target identification, preclinical studies, clinical trials, regulatory approval, and post-market surveillance. It involves multidisciplinary collaboration among scientists, researchers, clinicians, regulatory experts, and pharmaceutical companies to bring innovative therapies to market and address unmet medical needs.
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...VarunMahajani
Disruption of blood supply to lung alveoli due to blockage of one or more pulmonary blood vessels is called as Pulmonary thromboembolism. In this presentation we will discuss its causes, types and its management in depth.
1. KEYNOTE-407: Phase III Trial of Carboplatin +
Paclitaxel/nab-Paclitaxel ± Pembrolizumab in
Patients With Untreated Stage IV Squamous NSCLC
This activity is supported by educational grants from Amgen; Astellas; AstraZeneca;
Celgene Corporation; Eisai; Genentech; Janssen; Merck & Co., Inc.; and Seattle Genetics.
CCO Independent Conference Highlights*
of the 2018 ASCO Annual Meeting; June 1-5, 2018; Chicago, Illinois
*CCO is an independent medical education company that provides state-of-the-art medical information to
healthcare professionals through conference coverage and other educational programs.
2. Carboplatin + Paclitaxel/nab-Paclitaxel ±
Pembrolizumab in NSCLC (KEYNOTE-407): Background
Pembrolizumab: monoclonal antibody targeting PD-1
‒ Significantly improved OS and PFS with fewer AEs vs platinum-based
chemotherapy in patients with untreated advanced squamous or
nonsquamous PD-L1–positive NSCLC[1]
‒ Significantly improved OS and PFS when added to pemetrexed + a
platinum-based agent in patients with untreated metastatic
nonsquamous NSCLC, regardless of PD-L1 status[2]
Current prespecified second interim analysis evaluates efficacy and
safety of pembrolizumab addition to platinum-based chemotherapy in
patients with untreated metastatic squamous NSCLC[3]
1. Reck M, et al. N Engl J Med. 2016;375:1823-1833. 2. Gandhi L, et al. N Engl J Med.
2018;378:2078-2092. 3. Paz-Ares LG, et al. ASCO 2018. Abstract 105. Slide credit: clinicaloptions.com
3. Randomized, double-blind phase III trial
Primary endpoint: PFS by RECIST v1.1 (BICR), OS
Secondary endpoints: ORR and DoR by RECIST v1.1 (BICR), safety
KEYNOTE-407: Study Design
Paz-Ares LG, et al. ASCO 2018. Abstract 105. ClinicalTrials.gov. NCT02775435. Slide credit: clinicaloptions.com
Pembrolizumab + Carboplatin +
Paclitaxel or nab-Paclitaxel
3-wk cycles x 4
(n = 278)
Patients with untreated stage IV
squamous NSCLC, ECOG PS 0/1,
available tumor biopsy for PD-L1
assessment, no brain mets, and
no pneumonitis requiring
systemic steroids
(N = 559)
Stratified by PD-L1 TPS (< 1% vs ≥ 1%), taxane (paclitaxel
vs nab-paclitaxel), region (east Asia vs other)
Carboplatin AUC 6 Q3W, nab-paclitaxel 100 mg/m2 QW, paclitaxel 200 mg/m2 Q3W, pembrolizumab 200 mg Q3W.
*Upon confirmation of PD and safety criteria by BICR, optional crossover could occur during combination or monotherapy.
Placebo + Carboplatin +
Paclitaxel or nab-Paclitaxel
3-wk cycles x 4
(n = 281)
Pembrolizumab
up to 31 cycles
Placebo
up to 31 cycles
Pembrolizumab
up to 35 cycles
Crossover
allowed*
PD
4. KEYNOTE-407: Baseline Characteristics
Paz-Ares LG, et al. ASCO 2018. Abstract 105. Slide credit: clinicaloptions.com
Characteristic Pembro + Chemo (n = 278) Chemo (n = 281)
Median age, yrs (range) 65 (29-87) 65 (36-88)
Male, n (%) 220 (79.1) 235 (83.6)
ECOG PS 1, n (%) 205 (73.7) 191 (68.0)
Stable brain metastases, n (%) 20 (7.2) 24 (8.5)
Former/current smoker, n (%) 256 (92.1) 262 (93.2)
Enrolled in east Asia, n (%) 54 (19.4) 52 (18.5)
PD-L1 TPS ≥ 1%, n (%) 176 (63.3) 177 (63.0)
Paclitaxel chosen as taxane, n (%) 169 (60.8) 167 (59.4)
Prior thoracic radiation, n (%) 17 (6.1) 22 (7.8)
Prior (neo)adjuvant therapy, n (%) 5 (1.8) 8 (2.8)
5. KEYNOTE-407: PFS by RECIST v1.1 (BICR) in ITT Population
Paz-Ares LG, et al. ASCO 2018. Abstract 105. Reproduced with permission. Slide credit: clinicaloptions.com
Mos
Patients at Risk, n
PFS(%)
Median PFS, Mos (95% CI)
6.4 (6.2-8.3)
4.8 (4.3-5.7)
100
80
60
40
20
0
0 3 6 9 12 15 18 21
Pembro + Chemo
Chemo
54.7
70.1
0.56
(0.45-0.70)
< .0001
Events, % HR (95% CI) P Value
278
281
223
190
142
90
57
26
23
12
5
4
0
0
0
0
6. KEYNOTE-407: OS in ITT Population
Paz-Ares LG, et al. ASCO 2018. Abstract 105. Reproduced with permission. Slide credit: clinicaloptions.com
Mos
Patients at Risk, n
OS(%)
Median OS, Mos (95% CI)
15.9 (13.2-NE)
11.3 (9.5-14.8)
100
80
60
40
20
0
0 3 6 9 12 15 18 21
Pembro + Chemo
Chemo
30.6
42.7
0.64
(0.49-0.85)
0.0008
Events, % HR (95% CI) P Value
278
281
256
246
188
175
124
93
62
45
17
16
2
4
0
0
7. KEYNOTE-407: OS in Key Subgroups
Paz-Ares LG, et al. ASCO 2018. Abstract 105. Reproduced with permission. Slide credit: clinicaloptions.com
Subgroup
Overall
Age
< 65 yrs
≥ 65 yrs
Sex
Male
Female
ECOG PS
0
1
Region of enrollment
East Asia
Rest of world
Choice of taxane
Paclitaxel
Nab-paclitaxel
Deaths/Patients,
n/N
205/559
88/254
117/305
167/455
38/104
48/163
157/396
34/106
171/453
140/336
65/223
0.64 (0.49-0.85)
0.52 (0.34-0.80)
0.74 (0.51-1.07)
0.69 (0.51-0.94)
0.42 (0.22-0.81)
0.54 (0.29-0.98)
0.66 (0.48-0.90)
0.44 (0.22-0.89)
0.69 (0.51-0.93)
0.67 (0.48-0.93)
0.59 (0.36-0.98)
HR (95% CI)
Chemo BetterPembro + Chemo Better
0.1 0.5 1
8. KEYNOTE-407: PFS, OS by PD-L1 TPS
Paz-Ares LG, et al. ASCO 2018. Abstract 105. Slide credit: clinicaloptions.com
Survival by PD-L1 Expression,
Mos (95% CI)
Pembro + Chemo Chemo HR (95% CI)
Median PFS by RECIST v1.1 (BICR)
TPS < 1%
TPS 1% to 49%
TPS ≥ 50%
6.3 (6.1-6.5)
7.2 (6.0-11.4)
8.0 (6.1-10.3)
5.3 (4.4-6.2)
5.2 (4.2-6.2)
4.2 (2.8-4.6)
0.68 (0.47-0.98)
0.56 (0.39-0.80)
0.37 (0.24-0.58)
Median OS
TPS < 1%
TPS 1% to 49%
TPS ≥ 50%
15.9 (13.1-NE)
14.0 (12.8-NE)
NR (11.3-NE)
10.2 (8.6-13.8)
11.6 (8.9-17.2)
NR (7.4-NE)
0.61 (0.38-0.98)
0.57 (0.36-0.90)
0.64 (0.37-1.10)
Pembro + chemo: TPS < 1%, n = 95; TPS 1% to 49%, n = 103; TPS ≥ 50%, n = 73.
Chemo: TPS < 1%, n = 99; TPS 1% to 49%, n = 104; TPS ≥ 50%, n = 73.
9. KEYNOTE-407: Secondary Endpoints
Median follow-up: 7.8 mos (0.1-19.1)
Mean treatment duration
‒ Pembro + chemo: 6.3 mos
‒ Chemo: 4.7 mos
Paz-Ares LG, et al. ASCO 2018. Abstract 105. Slide credit: clinicaloptions.com
Response
Pembro +
Chemo
(n = 278)
Chemo
(n = 281)
ORR, % (95% CI)
57.9
(51.9-63.8)
38.4
(32.7-44.4)
CR, n (%) 4 (1.4) 6 (2.1)
PR, n (%) 157 (56.5) 102 (36.3)
SD, n (%) 78 (28.1) 104 (37.0)
PD, n (%) 17 (6.1) 39 (13.9)
Not evaluable,* n (%) 6 (2.2) 7 (2.5)
Not assessed,† n (%) 16 (5.8) 23 (8.2)
*Patients with ≥ 1 post-BL imaging assessment but none evaluable per
RECIST v1.1 (BICR). †Patients without ≥ 1 post-BL imaging assessment.
Outcome
Pembro +
Chemo
(n = 161)
Chemo
(n = 108)
Median DoR, mos
(range)
7.7
(1.1+ to 14.7+)
4.8
(1.3+ to 15.8+)
10. KEYNOTE-407: Safety
Paz-Ares LG, et al. ASCO 2018. Abstract 105. Slide credit: clinicaloptions.com
Summary of AE, n (%) Pembro + Chemo (n = 278) Chemo (n = 280)
All cause 273 (98.2) 274 (97.9)
Grade 3-5 194 (69.8) 191 (68.2)
Led to death
Treatment related
23 (8.3)
10 (3.6)
18 (6.4)
6 (2.1)
Led to discontinuation
All treatment
Any treatment
37 (13.3)
65 (23.4)
18 (6.4)
33 (11.8)
Immune-mediated and infusion reactions
Grade 3-5
Led to death
80 (28.8)
30 (10.8)
1 (0.4)
24 (8.6)
9 (3.2)
1 (0.4)
12. KEYNOTE-407: Conclusions
In patients with untreated metastatic squamous NSCLC, addition of pembrolizumab to
carboplatin + paclitaxel or nab-paclitaxel significantly improved survival regardless of PD-L1
expression level
‒ Median PFS: 6.4 vs 4.8 mos (P < .0001); median OS: 15.9 vs 11.3 mos (P = .0008)
ORR, DoR also improved with addition of pembrolizumab to chemotherapy in this setting
Safety profile consistent with known data for regimen constituents
‒ D/c rates for AEs low overall but numerically higher in pembrolizumab arm
‒ Immune-mediated AEs also more common in pembrolizumab arm; frequency/severity comparable
to studies with pembrolizumab monotherapy
Study investigators suggest that pembrolizumab + carboplatin + paclitaxel or nab-paclitaxel
should be a standard frontline treatment for metastatic squamous NSCLC with any PD-L1 TPS
Paz-Ares LG, et al. ASCO 2018. Abstract 105. Slide credit: clinicaloptions.com
13. clinicaloptions.com/oncology
Go Online for More CCO
Coverage of ASCO 2018!
Short slideset summaries and additional CME-certified analyses with expert faculty
commentary on key studies in:
Gastrointestinal cancer
Genitourinary cancer
Hematologic malignancies
Lung cancer